Product Name
AGPAT2, siRNA
Full Product Name
AGPAT2 siRNA (Human)
Product Synonym Names
1-acyl-sn-glycerol-3-phosphate acyltransferase beta; 1-acylglycerol-3-phosphate O-acyltransferase 2; 1-AGP acyltransferase 2; 1-AGPAT 2; Lysophosphatidic acid acyltransferase beta; LPAAT-beta
Product Gene Name
AGPAT2 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for O15120
Specificity
AGPAT2 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human AGPAT2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of AGPAT2 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
AGPAT2 sirna
siRNA to inhibit AGPAT2 expression using RNA interference
Applications Tested/Suitable for AGPAT2 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for AGPAT2. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001012745.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001012727.1
[Other Products]
UniProt Primary Accession #
O15120
[Other Products]
UniProt Secondary Accession #
O00516; O15106; Q5VUD3; Q5VUD4; Q9BSV7; Q9BWR7[Other Products]
UniProt Related Accession #
O15120[Other Products]
Molecular Weight
27,279 Da
NCBI Official Full Name
1-acyl-sn-glycerol-3-phosphate acyltransferase beta isoform b
NCBI Official Synonym Full Names
1-acylglycerol-3-phosphate O-acyltransferase 2
NCBI Official Symbol
AGPAT2 [Similar Products]
NCBI Official Synonym Symbols
BSCL; BSCL1; LPAAB; 1-AGPAT2; LPAAT-beta
[Similar Products]
NCBI Protein Information
1-acyl-sn-glycerol-3-phosphate acyltransferase beta
UniProt Protein Name
1-acyl-sn-glycerol-3-phosphate acyltransferase beta
UniProt Synonym Protein Names
1-acylglycerol-3-phosphate O-acyltransferase 2; 1-AGP acyltransferase 2; 1-AGPAT 2; Lysophosphatidic acid acyltransferase beta; LPAAT-beta
Protein Family
1-acyl-sn-glycerol-3-phosphate acyltransferase
UniProt Gene Name
AGPAT2 [Similar Products]
UniProt Synonym Gene Names
1-AGP acyltransferase 2; 1-AGPAT 2; LPAAT-beta [Similar Products]
UniProt Entry Name
PLCB_HUMAN
NCBI Summary for AGPAT2
This gene encodes a member of the 1-acylglycerol-3-phosphate O-acyltransferase family. The protein is located within the endoplasmic reticulum membrane and converts lysophosphatidic acid to phosphatidic acid, the second step in de novo phospholipid biosynthesis. Mutations in this gene have been associated with congenital generalized lipodystrophy (CGL), or Berardinelli-Seip syndrome, a disease characterized by a near absence of adipose tissue and severe insulin resistance. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jul 2008]
UniProt Comments for AGPAT2
AGPAT2: Converts lysophosphatidic acid (LPA) into phosphatidic acid by incorporating an acyl moiety at the sn-2 position of the glycerol backbone. Defects in AGPAT2 are the cause of congenital generalized lipodystrophy type 1 (CGL1); also known as Berardinelli-Seip congenital lipodystrophy type 1 (BSCL1) or Berardinelli-Seip syndrome. CGL1 is an autosomal recessive disorder characterized by marked paucity of adipose tissue, extreme insulin resistance, hypertriglyceridemia, hepatic steatosis and early onset of diabetes. Belongs to the 1-acyl-sn-glycerol-3-phosphate acyltransferase family. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: Lipid Metabolism - glycerophospholipid; Lipid Metabolism - glycerolipid; Membrane protein, integral; Lipid Metabolism - ether lipid; EC 2.3.1.51; Membrane protein, multi-pass; Transferase
Chromosomal Location of Human Ortholog: 9q34.3
Cellular Component: endoplasmic reticulum membrane; endoplasmic reticulum; integral to membrane
Molecular Function: 1-acylglycerol-3-phosphate O-acyltransferase activity
Biological Process: positive regulation of cytokine production; epidermis development; phospholipid metabolic process; glycerophospholipid biosynthetic process; phosphatidic acid biosynthetic process; triacylglycerol biosynthetic process; cellular lipid metabolic process; CDP-diacylglycerol biosynthetic process; positive regulation of cytokine and chemokine mediated signaling pathway
Disease: Lipodystrophy, Congenital Generalized, Type 1
Research Articles on AGPAT2
1. A changes serine in the acyltransferase NHX4D motif of AGPAT2, and intronic c.493-1G>C mutation destroy a splicing site that leads to exon 4 skipping and deletion of whole AGPAT2 substrate binding domain.">Data show that missense mutation c.299G>A changes serine in the acyltransferase NHX4D motif of AGPAT2, and intronic c.493-1G>C mutation destroy a splicing site that leads to exon 4 skipping and deletion of whole AGPAT2 substrate binding domain.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
